SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction
NCT00299832 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2016-11-18
Summary
Assessing the safety, efficacy and pharmacokinetics of SPP100 (Aliskiren) regimen in hypertensive patients with renal dysfunction
Conditions
Interventions
- DRUG
-
Aliskiren
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis · Novartis
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-04-30
- Primary Completion
- 2007-05-31
- Completion
- 2007-05-31
Countries
- Japan
More Related Trials
-
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
NCT00219128 ·Status: COMPLETED ·Phase: PHASE3
-
Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension
NCT00219037 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension
NCT00219050 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
NCT00260923 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria
NCT00097955 ·Status: COMPLETED ·Phase: PHASE2
-
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
NCT01113047 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
NCT00765947 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
NCT01237223 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
NCT00654875 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
NCT01042392 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study
NCT00706134 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension
NCT00705575 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension
NCT01070030 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg
NCT00529451 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
NCT00441064 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
NCT00739973 ·Status: COMPLETED ·Phase: PHASE3
-
Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet
NCT00518765 ·Status: COMPLETED ·Phase: PHASE3
-
A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)
NCT00246584 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
NCT00219154 ·Status: COMPLETED ·Phase: PHASE3
-
New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering
NCT01609959 ·Status: COMPLETED ·Phase: PHASE4
-
To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil
NCT06500689 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.
NCT00219024 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
NCT00219063 ·Status: COMPLETED ·Phase: PHASE3
-
Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
NCT00797862 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
NCT00219180 ·Status: COMPLETED ·Phase: PHASE3